Home
About
About The Guide to PHARMACOLOGY
About NC-IUPHAR
Contributors
Sponsors
Citing
Linking to us
FAQ
Disclaimer
Privacy and Cookie Policy
Targets
GPCRs
Ion channels
LGICs
VGICs
Other channels
Nuclear receptors
Kinases
Catalytic receptors
Transporters
Enzymes
Other protein targets
Target search
Target search tools
BLAST
Ligands
Ligand list
Ligand families
Ligand search
Diseases
Resources
Help
Tutorial
FAQ
Terms and symbols
Nomenclature guidelines
Publications
Downloads
Download data and reports
Web services
Slides and posters
News
Immunopharmacology Meeting 2018
Latest news
Hot topics
Latest pairings
Concise Guide to PHARMACOLOGY
Useful links
Advanced search
Target search
Target search tools
BLAST
Ligand search
Pharmacology search
Immuno Portal
Malaria Portal
Home
About
Help
Home
Ligands
secukinumab
secukinumab
GtoPdb Ligand ID: 8078
Synonyms:
AIN 457 | AIN457 | Cosentyx® | NVP-AIN457
secukinumab is an
approved drug
(Japan (2014), FDA and EMA (2015))
Compound class:
Antibody
Comment:
Peptide sequences for this antibody are available from its IMGT/mAb-DB entry.
This antibody is the subject of patent US7807155 [
2
].
Summary
Biological activity
Clinical data
References
Immunopharmacology
Selectivity at ligand targets
Key to terms and symbols
Click column headers to sort
Target
Sp.
Type
Action
Value
Parameter
Concentration range (M)
Reference
IL-17A
Hs
Antibody
Binding
9.9
p
K
d
-
2
⤷
p
K
d
9.9 (
K
d
1.22x10
-10
M) [
2
]
Description: Binding affinity for recombinant human IL-17
IL-17A
Hs
Antibody
Binding
8.7
pIC
50
-
2
⤷
pIC
50
8.7 (IC
50
2.1x10
-9
M) [
2
]
Description: Inhibition of IL-17-induced IL-6 production by human dermal fibroblasts.